In Vivo CAR T-Cell Therapy Spurs 100% ORR in Phase I

In the phase I inMMyCAR study of the in vivo chimeric antigen receptor (CAR) T-cell therapy KLN-1010, all 18 patients with multiple myeloma responded. None of the evaluable patients had minimal residual disease 1 month after treatment, suggesting that the therapy could prove clinically useful.